Mineralys Therapeutics adds Kristine Peterson and Lonnel Coats to board, expanding to nine directors
Mineralys Therapeutics, Inc.
Board appointed Kristine Peterson and Lonnel Coats effective Oct. 19, 2026, increasing board size from seven to nine directors.
Peterson named Class I director with term expiring at 2027 annual meeting and Audit Committee member; Coats Class II with term expiring at 2028 annual meeting and Compensation Committee member.
Each received on Oct. 19, 2026 an option for 16,600 shares vesting monthly over three years and an RSU award for 12,400 shares vesting annually over three years.
Board determined both satisfy Nasdaq independence requirements; no arrangements or Item 404(a) related-party transactions disclosed.
On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.
Mr. Coats was appointed as a Class II director, with a term expiring at the Company’s 2028 annual meeting of stockholders, and was also appointed to serve as a member of the Compensation Committee.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Kristine Peterson was appointed as Class I Director at Mineralys Therapeutics, Inc..
Action
appointed
Role
Class I Director
Exact text from the filing
On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven to nine directors.
Lonnel Coats was appointed as Class II Director at Mineralys Therapeutics, Inc..
Action
appointed
Role
Class II Director
Exact text from the filing
Mr. Coats was appointed as a Class II director, with a term expiring at the Company’s 2028 annual meeting of stockholders, and was also appointed to serve as a member of the Compensation Committee.
This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.